US 11,707,439 B2
Parenteral treatments involving aminoadamantane derivatives
Gurpartap Singh Sachdeva, Princeton Junction, NJ (US); Suresh Borsadia, Plainsboro, NJ (US); Kalpana Patel, West Windsor, NJ (US); and Krunal Raval, Gujarat (IN)
Assigned to Shinkei Therapeutics, Inc., Princeton, NJ (US)
Filed by Gurpartap Singh Sachdeva, Princeton Junction, NJ (US); Suresh Borsadia, Plainsboro, NJ (US); Kalpana Patel, West Windsor, NJ (US); and Krunal Raval, Gujarat (IN)
Filed on Apr. 6, 2020, as Appl. No. 16/840,561.
Claims priority of provisional application 62/830,830, filed on Apr. 8, 2019.
Prior Publication US 2020/0315991 A1, Oct. 8, 2020
Int. Cl. A61K 31/13 (2006.01); A61K 45/06 (2006.01); A61K 9/00 (2006.01)
CPC A61K 31/13 (2013.01) [A61K 9/0019 (2013.01); A61K 45/06 (2013.01)] 20 Claims
 
1. A method of treating traumatic brain injury (TBI) in a human subject comprising intravenously administering a composition consisting of a pharmacologically effective amount of amantadine or a pharmaceutically acceptable salt thereof in sterile water and wherein the composition is free of any other excipients, the composition has a volume of about 100 ml to about 1000 ml and the composition is administered once or twice daily at a daily dose of about 200 mg to about 400 mg amantadine or a pharmaceutically acceptable salt thereof at a rate of about 15 mg/hr to about 135 mg/hr.